Author:
John Steven A.,Zapata Juan P.,Dang Madeline,Pleuhs Benedikt,O’Neil Andrew,Hirshfield Sabina,Walsh Jennifer L.,Petroll Andrew E.,Quinn Katherine G.
Abstract
AbstractIntramuscular cabotegravir for long-acting injectable HIV pre-exposure prophylaxis (i.e., LAI-PrEP) was approved by the U.S. FDA in 2021. We sought to explore LAI-PrEP decision-making among a nationwide sample of young sexual minority men (YSMM) 17–24 years old. In 2020, HIV-negative/unknown YSMM (n = 41) who met CDC criteria for PrEP were recruited online to participate in synchronous online focus groups eliciting preferences and opinions about LAI-PrEP, as well as the impact of a potential self-administered option. Data were analyzed using inductive and deductive thematic analysis with constant comparison. Preferences and decision-making about LAI-PrEP varied widely among YSMM, with participants frequently comparing LAI-PrEP to oral PrEP regimens. We identified five key themes related to LAI-PrEP decision-making including concerns about adherence to PrEP dosing and clinic appointments, awareness and knowledge of PrEP safety and efficacy data, comfort with needles, minimizing PrEP stigma, and considerations of self-administration. YSMM acknowledged more PrEP options as beneficial to supporting uptake and persistence.
Funder
National Institute of Mental Health
National Center for Advancing Translational Sciences
Publisher
Springer Science and Business Media LLC
Reference62 articles.
1. Centers for Disease Control and Prevention. HIV Surveillance Report, 2019, vol. 32, 2021. http://www.cdc.gov/hiv/library/reports/hiv-surveillance.html.
2. US Food and Drug Administration. FDA approves first medication to reduce HIV risk. 2012. https://wayback.archive-it.org/7993/20170406045106/https://www.fda.gov/ForConsumers/ConsumerUpdates/ucm311821.htm.
3. Baeten, J. M. et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N. Engl. J. Med. 367(5), 399–410 (2012).
4. Choopanya, K. et al. Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): A randomised, double-blind, placebo-controlled phase 3 trial. Lancet 381(9883), 2083–2090 (2013).
5. Grant, R. M. et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N. Engl. J. Med. 363(27), 2587–2599 (2010).
Cited by
10 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献